Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA requests modifications to Bexxar BLA

Aug. 31, 1999

Herceptin approved in Canada for breast cancer therapy

Aug. 30, 1999

Berlex acquires marketing rights to Campath

Aug. 25, 1999

Chiron files long-term survival data for Proleukin with the FDA

Aug. 23, 1999

Clinical trials of SRL-172 in lung cancer are progressing

Aug. 20, 1999

Biomira's BLP25 cancer vaccine tested at higher dose and frequency

Aug. 17, 1999

CEA-Cide granted orphan drug status for ovarian cancer

Aug. 13, 1999

Vaccination with HPV16 peptides in advanced cervical carcinoma

Aug. 6, 1999

Phase I trial begins for SMART 1D10 antibody in non-Hodgkin's B-cell lymphoma

Aug. 5, 1999

Herceptin approved and launched in Switzerland

Aug. 4, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...